- Lexicon Pharmaceuticals (LXRX) slides 11% in premarket trading.
- Although top-line results from a Phase 2 study of LX1033 in IBS-d showed patients experienced "significant improvements over time," the company says "differences between placebo and LX1033 in stool consistency were not statistically significant."
- Here's CMO Pablo Lapuerta: "While this initial Phase 2a study was underway, we completed long-term toxicology studies which would allow us to conduct a Phase 2b study at doses informed by the current results and with a duration of 12 weeks." (PR)
Lexicon Pharmaceuticals falls on LX1033 top-line data
Dec 3 2013, 08:15 ET